Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.51 |
| ▸ | XPO1 | O14980 | 1/20 | 0.47 |
| ▸ | ELANE | P08246 | 2/20 | 0.39 |
| ▸ | MEN1 | O00255 | 2/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.39 |
| ▸ | PKM | P14618 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.37 |
| ▸ | MAPT | P10636 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.36 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
| ▸ | HPD | P32754 | 1/20 | 0.35 |
| ▸ | TYMS | P04818 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1592579 | 0.84 | LMNA (0.49) | LMNAELANEMEN1KMT2APKM | |
| SCHEMBL1592940 | 0.80 | XPO1 (0.46) | XPO1MEN1KMT2AMAPT | |
| SCHEMBL20880371 | 0.77 | XPO1 (0.51) | XPO1MEN1KMT2AALDH1A1KDM4E | |
| SCHEMBL1592361 | 0.76 | XPO1 (0.67) | LMNAXPO1MEN1KMT2AMAPT | |
| SCHEMBL24538005 | 0.75 | LMNA (0.62) | LMNAELANEMEN1KMT2APKM | |
| SCHEMBL1592533 | 0.75 | XPO1 (0.59) | XPO1ELANEMEN1KMT2AKDM4E | |
| SCHEMBL9724148 | 0.73 | LMNA (0.55) | LMNAMEN1KMT2APKMALDH1A1 | |
| SCHEMBL1592549 | 0.73 | XPO1 (0.56) | LMNAXPO1ALDH1A1MAPTSMN1; SMN2 | |
| SCHEMBL8134282 | 0.72 | XPO1 (0.56) | XPO1ALDH1A1MAPTTYMS | |
| SCHEMBL12704580 | 0.71 | POLB (0.44) | LMNAXPO1MEN1KMT2AALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 34 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2152692-B9 | COMPOUNDS WITH ANTI-CANCER ACTIVITY | CANBAS CO LTD (JP) | 2020-03-25 | — | — | EP | claimed |
| EP-2152692-B1 | COMPOUNDS WITH ANTI-CANCER ACTIVITY | CANBAS CO LTD (JP) | 2016-06-15 | — | — | EP | claimed |
| US-8415357-B2 | Compounds with anti-cancer activity | CANBAS CO., LTD. (JP) | 2013-04-09 | — | — | US | claimed |
| US-8084454-B2 | Cell cycle G2-checkpoint-abrogating 1-[(2-pyridyl)amino]-azoline-2,5-dione derivatives with at least one halogen group, to selectively sensitize cancer cells to DNA damaging reagents without additional anticarcinogenic treatment; cytolytic agents, antiproliferatives, apoptosis | CANBAS CO., LTD. (JP) | 2011-12-27 | — | — | US | claimed |
| US-20110092514-A1 | COMPOUNDS WITH ANTI-CANCER ACTIVITY | CANBAS CO., LTD. (JP) | 2011-04-21 | — | — | US | claimed |
| EP-2152692-A2 | COMPOUNDS WITH ANTI-CANCER ACTIVITY | Canbas Co. Ltd. (JP) | 2010-02-17 | — | — | EP | claimed |
| WO-2009031040-A2 | COMPOUNDS WITH ANTI-CANCER ACTIVITY | CANBAS CO., LTD. (JP) | 2009-03-12 | — | — | WO | claimed |
| US-20080275057-A1 | Compounds with anti-cancer activity | CANBAS CO., LTD. (JP) | 2008-11-06 | — | — | US | claimed |
| US-20230158005-A1 | Substituted Azole Dione Compounds with Antiviral Activity | STEMLINE THERAPEUTICS, INC. (US) | 2023-05-25 | — | — | US | disclosed |
| US-20230158005-A1 | Substituted Azole Dione Compounds with Antiviral Activity | STEMLINE THERAPEUTICS, INC. (US) | 2023-05-25 | — | — | US | disclosed |
| US-20230158005-A1 | Substituted Azole Dione Compounds with Antiviral Activity | STEMLINE THERAPEUTICS, INC. (US) | 2023-05-25 | — | — | US | disclosed |
| EP-4074704-A1 | QUINOLINE COMPOUNDS WITH ANTI-CANCER ACTIVITY | CanBas Co., Ltd. (JP) | 2022-10-19 | — | — | EP | disclosed |
| WO-2021194954-A1 | SUBSTITUTED AZOLE DIONE COMPOUNDS WITH ANTIVIRAL ACTIVITY | STEMLINE THERAPEUTICS, INC. (US) | 2021-09-30 | — | — | WO | disclosed |
| EP-2152692-B9 | COMPOUNDS WITH ANTI-CANCER ACTIVITY | CANBAS CO LTD (JP) | 2020-03-25 | — | — | EP | disclosed |
| US-20110092514-A1 | COMPOUNDS WITH ANTI-CANCER ACTIVITY | CANBAS CO., LTD. (JP) | 2011-04-21 | — | — | US | disclosed |
| EP-2152692-A2 | COMPOUNDS WITH ANTI-CANCER ACTIVITY | Canbas Co. Ltd. (JP) | 2010-02-17 | — | — | EP | disclosed |
| WO-2009031040-A2 | COMPOUNDS WITH ANTI-CANCER ACTIVITY | CANBAS CO., LTD. (JP) | 2009-03-12 | — | — | WO | disclosed |
| US-20080275057-A1 | Compounds with anti-cancer activity | CANBAS CO., LTD. (JP) | 2008-11-06 | — | — | US | disclosed |
| US-20080275057-A1 | Compounds with anti-cancer activity | CANBAS CO., LTD. (JP) | 2008-11-06 | — | — | US | disclosed |
| US-20080275057-A1 | Compounds with anti-cancer activity | CANBAS CO., LTD. (JP) | 2008-11-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110092514-A1 | COMPOUNDS WITH ANTI-CANCER ACTIVITY | CDKN1A, CDC25C, DDB1 | LMNA 2689/4885XPO1 280/4885ELANE 3403/4885 |
| US-20080275057-A1 | Compounds with anti-cancer activity | CDKN1A, CDC25C, DDB1 | LMNA 2689/4885XPO1 280/4885ELANE 3403/4885 |
| US-20230158005-A1 | Substituted Azole Dione Compounds with Antiviral Activity | MAVS, DDX18, ZC3HAV1 | LMNA 3376/4885XPO1 302/4885ELANE 324/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.